Post-Transplant Ixazomib Maintenance Prolongs Survival in Newly Diagnosed Myeloma
For patients with newly diagnosed multiple myeloma (MM) who relapse following autologous hematopoietic cell transplantation (AHCT), maintenance therapy with the oral proteasome inhibitor (PI)...
Carfilzomib Versus Bortezomib: Comparing Proteasome Inhibitors in Newly Diagnosed Myeloma
Carfilzomib plus melphalan and prednisone (KMP) failed to improve survival outcomes for patients with newly diagnosed multiple myeloma (MM) compared with bortezomib plus melphalan...
FDA Halts Trials of Venetoclax for Myeloma
The U.S. Food and Drug Administration (FDA) has issued a warning to health-care professionals and clinical investigators about the risks associated with the investigational...
FDA’s ODAC Rejects Selinexor for Myeloma
In an 8-to-5 vote, the U.S. Food and Drug Administration's (FDA’s) Oncologic Drug Advisory Committee (ODAC) decided against recommending accelerated approval of selinexor for...
How I Treat In Brief: Treating the Young Patient With Multiple Myeloma
Recently, Sara Gandolfi, MD; Claudia Paba Prada, MD; and Paul G. Richardson, MD, discussed the treatment of younger patients with multiple myeloma, balancing disease...
ELOQUENT-3: A New Elotuzumab-Based Triplet Combination in Previously Treated Myeloma
Results from the phase II ELOQUENT-3 trial demonstrate that the combination of elotuzumab plus pomalidomide and dexamethasone extended progression-free survival (PFS) compared with pomalidomide...
Lenalidomide Maintenance Extends Survival Over Observation Alone in Newly Diagnosed Myeloma
New results from the large phase III Myeloma XI trial confirm that maintenance therapy with lenalidomide improves progressionfree survival (PFS) over observation alone in...
BCMA-Targeting Antibody Associated With Clinical Activity in Previously Treated Myeloma
In a first-in-human trial published in Lancet Oncology, the anti–B-cell maturation antigen (BCMA) antibody GSK2857916 was associated with clinical activity and was reasonably well...
Salvage Transplant Versus Continuous Therapy: Insights From the Myeloma ReLApsE Trial
For patients with multiple myeloma (MM) that has relapsed following autologous hematopoietic cell transplantation (AHCT), a standard salvage therapy approach involves high-dose chemotherapy and...
Evaluating Ixazomib Regimens in Patients With Newly Diagnosed Myeloma
Two studies presented at the 2018 ASH Annual Meeting explored the use the oral proteasome inhibitor (PI) ixazomib in patients with newly diagnosed multiple...
Current Issue
April 2019, Volume 5, Issue 5
This issue features a look at the pitfalls of presenting and interpreting clinical trial data, the latest advances in transplant presented at the 2019 TCT Meetings, and more.
